Kersen(SH:603626) Mei Ri Jing Ji Xin Wen·2025-12-17 03:13Core Viewpoint - Kosen Technology is facing scrutiny over its decision to sell its profitable subsidiary, Kosen Medical, amid ongoing losses, raising questions about the company's future strategic direction and operational viability [1][2]. Group 1: Company Strategy and Financial Performance - Kosen Technology plans to sell Kosen Medical for 915 million RMB, achieving a significant valuation increase of 206.45%, which is intended to enhance its financial performance [1]. - The company has reported consecutive losses for two years, with projected net losses of 281 million RMB in 2023 and 477 million RMB in 2024, indicating ongoing financial challenges [2]. - The sale is part of a broader strategy to optimize business operations and restructure finances, aiming to return to profitability while focusing on high-growth areas such as thermal management modules and robotic components [2]. Group 2: Investor Concerns and Transparency - Investors express concerns regarding the potential impact of asset sales on their interests, questioning the rationale behind selling a profitable asset during a period of financial distress [2]. - Kosen Technology is urged to improve transparency in its disclosures, providing detailed information about the transaction, including valuation methods and expected future benefits, to reassure investors [2]. - The company is also advised to strengthen its strategic planning and clarify the pathways and expected returns of new business initiatives to build investor confidence in its future direction [2][3].